CAPRI 2 GOIM study: investigate the efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line.

NIAID Data Ecosystem2026-03-12 收录

BRAF野生型肿瘤疗效评估

RECIST标准治疗反应率

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2540493 数据链接链接失效反馈

官方服务：

资源简介：

Primary objectives: Response Rate (RR) per each line of therapy: assessed according to RECIST criteria 1.1 Primary endpoints: Response Rate (RR) per each line of therapy assessed according to RECIST criteria 1.1

创建时间：

2021-05-15

CAPRI 2 GOIM study: investigate the efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line.

资源简介：

相关数据集